Placid Jover Sells 14,150 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Placid Jover sold 14,150 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the sale, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $214,532.58. This represents a 67.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Teva Pharmaceutical Industries Trading Up 0.0%

Shares of NYSE TEVA opened at $31.51 on Wednesday. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The firm has a market capitalization of $36.23 billion, a PE ratio of 26.26, a PEG ratio of 10.54 and a beta of 0.72. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The business has a 50-day moving average price of $33.01 and a two-hundred day moving average price of $26.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Recent quarterly results and FY‑2026 guidance remain supportive — Teva reported a Q4 EPS and revenue beat and set FY‑2026 EPS guidance of 2.570–2.770, with y/y revenue growth (~11.4%), which underpins investor confidence and helps explain upward pressure on the shares. MarketBeat TEVA coverage
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Scotiabank, Barclays, Truist, Goldman Sachs, others) have raised targets and ratings this quarter, boosting buy-side interest and supporting the stock’s gain.
• Neutral Sentiment: Management presentations at conferences — transcripts from the Leerink and Barclays healthcare conferences are now available; investors will scan these for pipeline updates, margin/cost commentary and capital‑allocation signals but they’ve not yet produced major new guidance. Leerink transcript Barclays transcript
• Negative Sentiment: Concentrated insider selling disclosed (filings show March 5 trades) — multiple senior executives sold shares at an average price of ~$31.67, including CEO Richard D. Francis (20,025 shares) and several EVPs; such sizable, coordinated disclosures can weigh on sentiment even if sales are routine or pre‑planned. Example SEC filing (CEO sale)
• Negative Sentiment: Media reports amplifying insider sales — outlets flagged the CEO and other executive sales, which can increase investor caution and short‑term volatility even when fundamentals remain solid. Media coverage of insider sales

Analysts Set New Price Targets

TEVA has been the subject of a number of research analyst reports. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Scotiabank upped their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Bank of America boosted their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. lifted its stake in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.